FLKS vs. AEZS, AKTX, NCNA, MTEM, VIRI, CYCN, HEPA, ATHE, UPC, and MBRX
Should you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Aeterna Zentaris (AEZS), Akari Therapeutics (AKTX), NuCana (NCNA), Molecular Templates (MTEM), Virios Therapeutics (VIRI), Cyclerion Therapeutics (CYCN), Hepion Pharmaceuticals (HEPA), Alterity Therapeutics (ATHE), Universe Pharmaceuticals (UPC), and Moleculin Biotech (MBRX). These companies are all part of the "medical" sector.
Flex Pharma (NASDAQ:FLKS) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
14.4% of Flex Pharma shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 7.6% of Flex Pharma shares are held by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Flex Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
Aeterna Zentaris has a net margin of -368.01% compared to Flex Pharma's net margin of -1,208.42%. Aeterna Zentaris' return on equity of -63.20% beat Flex Pharma's return on equity.
Aeterna Zentaris has a consensus price target of $15.00, indicating a potential upside of 668.25%. Given Aeterna Zentaris' higher probable upside, analysts plainly believe Aeterna Zentaris is more favorable than Flex Pharma.
Aeterna Zentaris received 58 more outperform votes than Flex Pharma when rated by MarketBeat users. However, 73.23% of users gave Flex Pharma an outperform vote while only 62.54% of users gave Aeterna Zentaris an outperform vote.
In the previous week, Aeterna Zentaris had 4 more articles in the media than Flex Pharma. MarketBeat recorded 4 mentions for Aeterna Zentaris and 0 mentions for Flex Pharma. Aeterna Zentaris' average media sentiment score of 0.36 beat Flex Pharma's score of 0.00 indicating that Aeterna Zentaris is being referred to more favorably in the news media.
Aeterna Zentaris has higher revenue and earnings than Flex Pharma.
Summary
Aeterna Zentaris beats Flex Pharma on 10 of the 15 factors compared between the two stocks.
Get Flex Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flex Pharma Competitors List
Related Companies and Tools
